Bendamustine Hydrochloride

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy Favorable safety profile with no dose-limiting toxicities supports plan to enable same-day discharge post FT819 treatment broadening patient accessibility All patients surpassing a 3-month post-treatment time point (n=5) showed significant reductions in the SLE Disease Activity Index (SLEDAI-2K) score and Physician’s Global Assessment (PGA) SLE patients with lupus nephritis (LN) surpassing a 3-month post-treatment time point (n=2) achieved complete renal response (CRR) at 6 months; first patient continues in drug-free Definition of Remission in SLE (DORIS) at 15 months follow-up Cumulative clinical dataset provides clear evidence for rapid CD19+ B cell depletion and immune remodeling toward a naïve and less pathogenic B-cell repertoire SAN DIEGO, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients for broad accessibility, today announced new and updated data from the first 10 patients dosed with FT819 in a Phase 1 clinical trial for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) at the American College of Rheumatology (ACR) Convergence 2025 in Chicago. “This promising initial clinical data demonstrates that FT819 can deliver transformative outcomes in patients with moderate-to-severe SLE, particularly with reduced or no conditioning chemotherapy,” said Bob Valamehr, Ph.D., M.B.A., President and Chief Executive Officer of Fate Therapeutics. “Having shown meaningful and durable clinical activity, a safety profile enabling plans for same-day discharge, and robust enrollment from the first four enrolling clinical sites, we expect accelerated patient enrollment as additional sites join the study. With many more sites now participating, we aim to promptly complete our Phase 1 trial. In addition, under our RMAT designation, we continue to engage with the FDA on a registrational study design with the goal of initiating a pivotal study next year. We are making great progress on our mission to make FT819 available on-demand, in a true off-the-shelf and cost-effective manner, with the potential to help patients suffering with SLE and other autoimmune diseases.” New and Updated Clinical Data Summary The Company is currently conducting a multi-center, Phase 1 clinical trial of FT819, its off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate, for the treatment of patients with moderate-to-severe SLE, including lupus nephritis and extrarenal lupus (NCT06308978). The study is designed to evaluate the safety, pharmacokinetics, and activity of a single dose of FT819 administered to patients with active refractory lupus with either (i) a less-intensive conditioning regimen (Regimen A; fludarabine (flu)-free conditioning consisting of either cyclophosphamide alone or bendamustine alone), or (ii) a conditioning-free regimen to patients on standard-of-care maintenance therapy (Regimen B). As of the data cut-off date of September 25, 2025, 10 patients (8 on Regimen A, 2 on Regimen B) have been treated with FT819, providing the following key insights: Less-intensive Conditioning Regimen Active Lupus Nephritis. Five patients with active refractory lupus nephritis (prior therapies range between 7 and 8, with all patients having received prior B-cell targeted therapy; baseline SLE Disease Activity Index (SLEDAI-2K) ranging between 8 and 20) were treated with a single dose of FT819 in the less-intensive conditioning regimen. As of the data cut-off date, two patients who were treated at dose level 1 (DL1, 360 million cells) had surpassed the 3-month evaluation timepoint and exhibited significant reductions of 16 and 12 points, respectively, in SLEDAI-2K from baseline and importantly, Urine Protein-to-Creatinine ratio (UPCr) reduction to < 0.5 mg/mg at 6 months. The patient who exhibited a 16 point SLEDAI-2K reduction discontinued steroids and achieved DORIS (definition of remission in SLE) and complete renal response (CRR) at 6 months and remains in steroid-free DORIS and CRR at the 15-month follow-up. The second patient exhibited a 12 point reduction in SLEDAI-2K and achieved CRR at 6 months; however, this patient subsequently experienced a disease flare and at the 12-month evaluation timepoint is under consideration for retreatment with FT819. Extrarenal Lupus. Three patients with active moderate-to-severe extrarenal lupus (prior therapies ranging between 3 and 10; baseline SLEDAI-2K ranging between 14 and 18) were treated with a single dose of FT819 in the less-intensive conditioning regimen. As of the data cut-off date, two patients had surpassed the 3-month evaluation timepoint. Both patients were treated at dose level 2 (DL2, 900 million cells). The first patient exhibited a significant reduction of SLEDAI-2K from 18 to 10 at one-month post-treatment; however, this patient was restarted on anifrolumab two months after treatment with FT819, which the patient had been on for the previous 3 years. SLEDAI-2K score and PGA continued to improve thereafter, and DORIS was achieved at 6 months post-treatment with FT819. Notably, these results were not previously achieved for this patient with treatment with combination therapy that included anifrolumab prior to starting treatment with FT819. The second patient also demonstrated significant reduction in SLEDAI-2K score to 6 from a baseline of 16, a meaningful reduction of PGA to 0.4 from a baseline of 2.2 and dramatically improved FACIT score at the 3-month evaluation timepoint. Conditioning-free Regimen Add-on to Maintenance Therapy. Two patients were treated with a single dose of FT819 at 360 million cells in the conditioning-free regimen as an add-on to mycophenolate mofetil maintenance therapy (one patient with extrarenal lupus with prior therapies = 5, baseline SLEDAI-2K = 8; and a second patient with lupus nephritis prior therapies = 8, baseline SLEDAI-2K = 17). As of the data cut-off date, the patient with extrarenal lupus had surpassed the 3-month evaluation timepoint and achieved low lupus disease activity state (LLDAS) by 3 months from FT819 administration, which was maintained at the most recent follow-up at 9 months. The patient also experienced meaningful reductions in SLEDAI-2K to 2 from 8 at baseline and in PGA to 0.5 from 2 at baseline, with steroids that were tapered to less than 5 mg / day. Safety In more than 60 patients treated with FT819 across autoimmune disease and oncology, favorable safety profile continues to be observed with low incidence of low-grade cytokine release syndrome (CRS), no events of immune effector cell-associated neurotoxicity (ICANS), and no events of graft-versus-host disease (GvHD). Specifically, in the 8 safety-evaluable patients treated with FT819 for SLE with at least one month follow-up as of the data cut-off date: there have been no events of ICANS, no events of GvHD, and 3 patients who experienced low-grade CRS (Grade 2 in maximum severity in 1 patient, Grade 1 in maximum severity in 2 patients); no dose-limiting toxicities were observed in any patient; and all patients were discharged following a short-duration of hospitalization post infusion of FT819, supporting the potential for outpatient administration and same-day discharge. there have been no events of ICANS, no events of GvHD, and 3 patients who experienced low-grade CRS (Grade 2 in maximum severity in 1 patient, Grade 1 in maximum severity in 2 patients); no dose-limiting toxicities were observed in any patient; and all patients were discharged following a short-duration of hospitalization post infusion of FT819, supporting the potential for outpatient administration and same-day discharge. Translational In patients treated with less-intensive conditioning chemotherapy, rapid and sustained CD19+ B cell depletion was observed, positively correlating with dose escalation. Upon return of the B cell compartment, naïve B cell emergence beyond baseline levels was observed, suggestive of an immune reset and correlative to reduction in disease burden. In patients treated without conditioning chemotherapy, a meaningful reduction in CD19+ B cells was also observed, alongside reduction in expanded B-cell clones and remodeling of the B cell compartment that correlated with improvement in disease activity scores. These observations underscore the unique ability of FT819 to remodel the B-cell repertoire toward a more naïve and less pathogenic state without the need for intensive conditioning chemotherapy. The mechanistic remodeling of the B cell compartment supports immune restoration as a driver of clinical remission, reinforcing transformative potential of FT819 in autoimmune disease treatment. Program Expansion and Outlook The Company has initiated independent dose-expansion cohorts in anti-neutrophilic cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). In addition, the Company is actively engaged under its Regenerative Medicine Advanced Therapy (RMAT) designation with the U.S. Food and Drug Administration (FDA) to align on a registrational study design with the goal to initiate a pivotal study in 2026. The Company currently has approximately 600 cryopreserved drug product bags of FT819 in inventory available for treatment of patients. Below are links to the Company Presentations at the 2025 ACR Convergence: Sunday, October 26, 2025 Poster Presentation | Abstract #0663 iPSC-Derived, Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy Session Title: Systemic Lupus Erythematosus – Treatment Poster I Session Time: 11:30AM – 1:30PM ET Monday, October 27, 2025 Poster Presentation | Abstract #1270 Increasing Participation in the FT819 Cell Therapy Trial Amongst People Living with Lupus: A Focus Group Study Session Title: Patient Outcomes, Preferences, & Attitudes Poster II Session Time: 11:30AM – 1:30PM ET Tuesday, October 28, 2025 Poster Presentation | Abstract #2454 Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-derived CAR T-cell Therapy Session Title: Systemic Lupus Erythematosus – Treatment Poster III Session Time: 11:30AM – 1:30PM ET About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company’s product candidates, including FT819, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the Company’s plans to complete IND-enabling studies and to submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the availability of data from the Company’s clinical trials and the Company’s plans to provide updates on its clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, and the Company’s clinical and product development strategy. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.com Source: Fate Therapeutics, Inc.

关 注  健 康 CLL/SLL   慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤是一种惰性的癌症，慢性淋巴细胞白血病与小淋巴细胞淋巴瘤属于同一种疾病，但在慢性淋巴细胞白血病中，癌细胞主要存在于血液和骨髓中；在小淋巴细胞淋巴瘤中，癌细胞主要存在于淋巴结中。慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤属于非霍奇金淋巴瘤的一种类型，也可简称为 CLL/SLL。 维奈克拉是一种口服靶向治疗药物，已获美国食品药品监督管理局（FDA）批准，用于一线治疗及复发/难治性CLL/SLL。维奈克拉的主要作用机制是抑制 B 细胞淋巴瘤 - 2（Bcl-2）蛋白，进而诱导恶性 CLL/SLL 细胞凋亡；与此同时，越来越多的研究数据显示，该药物对 T 细胞的活性与功能也存在影响。 图片【1】来源于Pixabay 维奈克拉抑制 BCL-2 在CLL/SLL中的应用 癌细胞会劫持多种细胞进程，以获得增殖和存活优势。其中一个例子便是抑制凋亡 —— 这是真核细胞固有的程序性死亡过程。BCL-2 家族促存活蛋白（包括 BCL-2 本身、BCL-XL、BCL-W、MCL-1 等）会以不同的特异性，与含 BH3 结构域的促凋亡蛋白（如 BAX、BAK）相互作用，从而抑制凋亡。癌细胞会过表达 BCL-2 家族促存活蛋白，以此抵抗遗传毒性应激、辐射及化疗的作用。18 号染色体异常（BCL-2 基因位点所在染色体）常见于多种非霍奇金淋巴瘤（如滤泡性淋巴瘤中的 t (14:18) 易位），但在慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤（CLL/SLL）中较少见。不过，慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤（CLL/SLL）中存在其他导致 BCL-2 过表达的机制，包括 miR-15/16 抑制作用丧失引发的 BCL2 翻译增强。miR-15/16 位于 13 号染色体上，该染色体区域（13q14.3）是慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤（CLL/SLL）患者中最常检测到的染色体异常位点。因此，通过抑制 BCL-2 直接作用于凋亡机制，被作为CLL/SLL的治疗策略展开研究。 早期阻断 BCL-2 促存活信号的策略，聚焦于泛 BCL-2 家族抑制剂 ABT-263（navitoclax）和 GX015-070（obatoclax）。这类药物被归为 BH3 模拟物，设计用途是结合并抑制抗凋亡 BCL-2 家族蛋白（包括 BCL-2、BCL-XL），从而以 BAX/BAK 依赖的方式启动凋亡。这两种药物在CLL/SLL患者中均具有活性，其中纳维托克拉斯单药治疗的总缓解率（ORR）达 35%。但纳维托克拉斯和奥巴托克拉斯存在局限性：用药初期数天内会出现剂量依赖性血小板减少，原因是血小板生成过程中需要 BCL-XL 的参与。 为提高耐受性，研究人员研发出 BCL-2 特异性 BH3 模拟物 ABT-199（即维奈克拉）。研究以obatoclax结合 BCL-2 的三维晶体结构为基础，通过逆向工程对obatoclax进行改造，增强其对 BCL-2 蛋白 P4 疏水口袋的特异性结合能力。该设计使维奈克拉对 BCL-2 的亲和力达亚纳摩尔级，对 BCL-2 的特异性是 BCL-XL 的 200 倍以上。在非霍奇金淋巴瘤（NHL）细胞系中，维奈克拉的疗效与 BCL-2 表达水平相关；在小鼠异种移植模型中，其与bendamustine、rituximab联用具有协同作用。重要的是，在动物模型中，维奈克拉引发的血小板减少显著少于navitoclax。基于此，研究人员在 3 例复发 / 难治性CLL/SLL患者中，测试了剂量为 100mg 或 200mg 的维奈克拉。3 例患者均在 24 小时内出现可触及淋巴结肿大缩小，且实验室检查显示存在肿瘤溶解综合征（TLS）的证据。 这些积极数据推动了一项扩展 I 期剂量递增试验（M12-175），该试验纳入 116 例复发 / 难治性CLL/SLL患者，测试剂量为每日 150mg 至 1200mg 的维奈克拉。试验纳入的是历史上治疗难度较大的人群：89% 的患者至少存在 1 项不良特征，既往接受治疗方案的中位数为 3 种。维奈克拉具有口服生物利用度，血清浓度达峰时间为 6-8 小时，半衰期约为 19 小时。根据药代动力学特征，扩展队列中采用的目标最大剂量为每日 400mg。 在这一经过多线治疗的人群中，维奈克拉在所有测试剂量下均具有活性：总缓解率（ORR）达 79%，完全缓解率（CR）达 20%。达到完全缓解的中位时间为 6 个月，另有 3 例患者在 1 年后达到完全缓解。疗效覆盖所有分析的高危亚组，包括氟达拉滨耐药患者（总缓解率 79%）和 IGHV 未突变患者（总缓解率 76%）。即使是携带 TP53 突变或 17p 缺失（del (17p)）的患者，总缓解率也达 71%，与总体试验人群相当。对试验患者原代样本的体外研究进一步显示：维奈克拉诱导的凋亡不依赖于 TP53，且无论 TP53 状态如何，维奈克拉的半数致死浓度（LC50）均相似。维奈克拉的积极疗效推动了一项 II 期扩展试验（M13-982），该试验纳入 107 例复发 / 难治性 17p 缺失（del (17p)）慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤（CLL/SLL）患者，结果显示总缓解率仍为 79%。基于此项结果，美国食品药品监督管理局（FDA）于 2016 年批准维奈克拉用于既往接受过治疗的 17p 缺失慢性淋巴细胞白血病 / 小淋巴细胞淋巴瘤（CLL/SLL）患者。 图片【2】来源于Pixabay 维奈克拉联合抗 CD20 免疫治疗在CLL/SLL中的应用 一项早期 II 期试验显示，在未经治疗的 CLL/SLL 患者中，rituximab联合navitoclax的客观缓解率（ORR）为 70%，而单独使用Rituximab的客观缓解率（ORR）仅为 35%。然而，由于维奈克拉的临床前研究数据前景良好，该试验提前终止。 首个正式验证维奈克拉联合rituximab（VR 方案）疗效的研究，是 2017 年初发表的 Ib 期 M13-365 试验，该试验纳入了 49 例复发或难治性 CLL/SLL 患者。在剂量扩展队列中，患者初始服用维奈克拉 20mg，之后每周递增剂量，在 5 周内达到每日 400mg 的维持剂量。在维奈克拉达到目标剂量 1 周后，开始每月给予Rituximab治疗（首次剂量为 375mg/m²，后续剂量为 500mg/m²）。试验人群中，患者既往接受治疗的中位次数为 2 次，90% 的患者曾接受过rituximab治疗，近半数患者被判定为Rituximab难治性。尽管如此，VR 方案仍实现了 86% 的客观缓解率（ORR）和 51% 的完全缓解率（CR）。 M13-365 试验将骨髓微小残留病（MRD）评估预设为探索性目标。在 CLL/SLL 中，采用四色流式细胞术检测，若每 10⁴个白细胞中肿瘤细胞少于 1 个，则定义为不可检测微小残留病。57% 的患者达到了骨髓不可检测微小残留病，这一比例显著高于复发 / 难治性 CLL/SLL 患者接受化学免疫治疗或 B 细胞信号抑制剂治疗的历史数据。在达到完全缓解的患者中，不可检测微小残留病的发生率高达 80%。相应地，不可检测微小残留病患者的 2 年持续缓解率为 100%，而可检测到微小残留病患者的 2 年持续缓解率仅为 71%。 该研究方案允许达到完全缓解或骨髓不可检测微小残留病的患者停用维奈克拉。共有 10 例达到完全缓解且为不可检测微小残留病的患者停止治疗，停药后均未出现疾病进展，其中 3 例患者停用维奈克拉后缓解状态维持超过 12 个月。2 例达到完全缓解但可检测到微小残留病的患者，在停用维奈克拉约 24 个月后出现疾病进展。重要的是，这 2 例患者在重新开始维奈克拉治疗后均再次获得缓解，这证实了一个概念：患者达到深度缓解（完全缓解或不可检测微小残留病）后，有可能停用维奈克拉；而当疾病进展时，重新启动以维奈克拉为基础的治疗或许是可行的。 III 期国际随机 MURANO 试验对 VR 方案的良好疗效进行了明确评估，该试验将 VR 方案与标准免疫化疗进行了比较。研究共纳入 389 例复发难治性 CLL/SLL 患者，随机分为两组：一组接受 6 个周期的bendamustine联合Rituximab（即 BR 方案）免疫化疗；另一组接受为期 2 年的持续维奈克拉治疗，在维奈克拉初始 5 周剂量递增完成后，加用 6 个月的每月 1 次Rituximab治疗。VR 方案的优势十分显著：其 24 个月无进展生存期（PFS）为 84.9%，而 BR 方案为 36.3%（风险比 HR=0.17），达到了试验预设的无进展生存期主要终点。次要疗效终点同样倾向于 VR 方案：VR 方案的 24 个月总生存期为 91.9%，而 BR 方案为 86.6%。独立审查委员会在联合治疗结束时（治疗 9 个月）评估的客观缓解率显示，VR 方案为 92.3%，BR 方案为 72.3%。此外，VR 方案在完全缓解率和伴不完全血液学恢复的完全缓解率方面也更具优势（26.8% vs 8.2%）。针对存在del (17p)和 TP53 基因突变患者的预设亚组分析证实，VR 方案在这些患者群体中同样能带来相似的无进展生存期获益。试验要求两组患者在治疗 9 个月时，通过流式细胞术和 / 或等位基因特异性寡核苷酸聚合酶链反应（ASO-PCR）进行外周血（PB）微小残留病评估。结果显示，治疗 9 个月时，VR 方案的外周血不可检测微小残留病率为 62.4%，而 BR 方案为 13.3%；在 VR 方案治疗期间的任意时间点，外周血不可检测微小残留病率高达 83.5%。基于这些结果，美国食品药品监督管理局（FDA）于 2018 年 6 月扩大了维奈克拉联合Rituximab方案的批准范围，将其用于所有既往至少接受过一次治疗的 CLL/SLL 患者，无论患者是否存在 17 号染色体缺失。 口服 BCL2 抑制剂维奈克拉在 CLL/SLL 治疗中已被证实具有优异疗效。维奈克拉与抗 CD20 单克隆抗体或 B 细胞受体（BCR）通路抑制剂联合使用时，展现出产生高质量缓解的潜力，包括高比例的不可检测微小残留病，这使得患者在维持持续缓解的前提下能够停药。 参考来源： [1]https://www.tandfonline.com/doi/full/10.2147/BLCTT.S177009#d1e504 [2]https://ashpublications.org/blood/article/142/Supplement%201/6518/505487/Venetoclax-Pre-Treatment-of-CLL-SLL-Patients [3]https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma 图片来源： 【1】https://pixabay.com/illustrations/dna-analysis-research-3539309/ 【2】https://pixabay.com/photos/lab-research-chemistry-test-217043/ 免责声明：本文仅作信息交流之目的，文中观点不代表中毅医药立场，亦不代表支持或反对文中观点。本文也不是治疗方案推荐，如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本消息内容包括部分图片来源于Pixabay等网站，文章内容来源于参考来源的网站，如有版权问题请联系我们，予以删除。 关于中毅医药 上海中毅医药科技发展有限责任公司（简称：中毅医药），以“Everything For Patients (一切为了患者)”为核心理念，致力于提供高品质、一站式的临床试验患者解决方案。中毅医药整合线上线下资源，连接中国与全球医疗网络，提供患者招募和患者保留服务，全力加速新药研发、提升患者体验。公司使命: Everything For Patients 联系我们 021-64087833 17269776607微信同号 上海市徐汇区漕溪北路18号上海实业大厦14B www.zhongyimedical.com bd@zy-cro.com